| gap-pubmed-20260410- | What neurobiological targets emerge from microbiota-targeted interventions for e | resolved | 0.72 | 0.00 | 2026-04-10 | 0 | | therapeutic-neuroscience |
| gap-pubmed-20260410- | How do microbiota-interoception-reward interactions differ between under-eating | open | 0.76 | 0.00 | 2026-04-10 | 0 | | eating-behavior-neurobiology |
| gap-pubmed-20260410- | What are the specific molecular mechanisms by which gut microbial signals modula | open | 0.80 | 0.00 | 2026-04-10 | 0 | | reward-neurocircuitry |
| gap-pubmed-20260410- | What determines the specificity of LGI1-OPALIN interaction versus other potentia | open | 0.75 | 0.00 | 2026-04-10 | 0 | | myelination-biology |
| gap-pubmed-20260410- | How does OPALIN function as both a paranodal structural protein and an LGI1 sign | open | 0.73 | 0.00 | 2026-04-10 | 0 | | myelination-biology |
| gap-pubmed-20260410- | What downstream signaling pathways mediate LGI1/OPALIN complex effects on Sox10 | open | 0.80 | 0.00 | 2026-04-10 | 0 | | myelination-biology |
| gap-pubmed-20260410- | Why do genetic studies on levodopa efficacy and adverse effects show mostly inco | open | 0.72 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What molecular mechanisms link the six common genes (UBC, SNCA, FYN, SRC, CAMK2A | open | 0.80 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What determines the temporal sequence of pluripotency enhancer selection during | open | 0.75 | 0.00 | 2026-04-10 | 0 | | cellular-reprogramming |
| gap-pubmed-20260410- | How does OSK-induced somatic TF redistribution mechanistically drive neuronal de | open | 0.79 | 0.00 | 2026-04-10 | 0 | | cellular-reprogramming |
| gap-pubmed-20260410- | Why do transferred mitochondria cause oxidative damage despite being metabolical | open | 0.82 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What molecular mechanisms drive excessive ROS generation when mitochondrial geno | open | 0.80 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | How does disrupted cochlear patterning lead to the formation of ectopic sensory | open | 0.75 | 0.00 | 2026-04-10 | 0 | | sensory-neurobiology |
| gap-pubmed-20260410- | What is the direct molecular mechanism by which Meis2 regulates Sonic hedgehog s | open | 0.80 | 0.00 | 2026-04-10 | 0 | | developmental-neurobiology |
| gap-pubmed-20260410- | How do semaglutide-induced metabolite changes specifically contribute to neuroac | open | 0.81 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What are the specific molecular mechanisms by which gut microbiota changes media | open | 0.80 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | How do cellular aberrations quantitatively correlating with disease severity con | open | 0.76 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What molecular mechanisms cause impaired metabolic flexibility in MPAN patient f | resolved | 0.80 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | Why do 65% of ASD cases show no detectable genetic variants despite comprehensiv | open | 0.75 | 0.00 | 2026-04-10 | 0 | | neurodevelopment |
| gap-pubmed-20260410- | What functional mechanisms link KMT2C, FOXP2, and MAN1B1 variants to ASD pathoge | open | 0.80 | 0.00 | 2026-04-10 | 0 | | neurodevelopment |
| gap-pubmed-20260410- | What determines the specificity of oxytocin's protection for dopaminergic versus | open | 0.75 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | How does oxytocin's neuroprotective role reconcile with its established prosocia | open | 0.68 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What upstream mechanisms cause oxytocin reduction in PD patients and how does th | resolved | 0.80 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | Why do complete versus anterior-only callosotomies show different efficacy patte | open | 0.74 | 0.00 | 2026-04-10 | 0 | | epilepsy-neurosurgery |
| gap-pubmed-20260410- | What mechanisms determine optimal patient selection criteria for corpus callosot | open | 0.77 | 0.00 | 2026-04-10 | 0 | | epilepsy-neurosurgery |
| gap-pubmed-20260410- | Why is the mPFC selectively vulnerable to METH-induced depressive pathology comp | open | 0.77 | 0.00 | 2026-04-10 | 0 | | addiction-neurobiology |
| gap-pubmed-20260410- | How does parthenolide specifically modulate ADORA2A signaling to produce antidep | partially_addressed | 0.87 | 0.00 | 2026-04-10 | 1 | 2026-04-25 | neuropharmacology |
| gap-pubmed-20260410- | Which specific mislocalized mRNAs drive neurodegeneration in ALS patients? | resolved | 0.82 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | How do ALS-associated TDP-43 mutations produce similar mRNA mislocalization as c | resolved | 0.87 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What is the molecular mechanism by which TDP-43 couples mRNA destabilization to | resolved | 0.85 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What role do tau-positive glial inclusions play in disease pathogenesis versus b | open | 0.78 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | How do tau isoform alterations specifically determine glial inclusion morphology | open | 0.76 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What mechanisms drive the formation of disease-specific tau-positive glial inclu | open | 0.80 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | How do altered microbiomes and intestinal barrier dysfunction specifically impac | open | 0.76 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | Why are serum biomarker results for predicting neurodegeneration in IBD patients | open | 0.83 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What specific mechanisms link IBD-induced systemic inflammation to neurodegenera | open | 0.80 | 0.00 | 2026-04-10 | 0 | | neuroinflammation |
| gap-pubmed-20260410- | How do retinal microglial changes temporally correlate with brain pathology in A | open | 0.83 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What molecular mechanisms drive the biphasic microglial activation pattern in re | open | 0.80 | 0.00 | 2026-04-10 | 0 | | neuroinflammation |
| gap-pubmed-20260410- | Can senolytic therapy prevent radiation brain injury when administered prophylac | open | 0.85 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What specific autophagy pathways are defective in radiation-induced pericyte sen | partially_addressed | 0.87 | 0.00 | 2026-04-10 | 1 | 2026-04-25 | neurodegeneration |
| gap-pubmed-20260410- | How does pericyte senescence mechanistically promote glioma cell growth and inva | partially_addressed | 0.89 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | How do VTAVgat-Sst cells simultaneously coordinate sleep promotion and HPA axis | open | 0.77 | 0.00 | 2026-04-10 | 0 | | neuroendocrinology |
| gap-pubmed-20260410- | What determines whether stress-induced sleep promotes resilience versus patholog | open | 0.76 | 0.00 | 2026-04-10 | 0 | | stress-neurobiology |
| gap-pubmed-20260410- | How do VTAVgat-Sst cells maintain enhanced activity for hours after transient st | open | 0.80 | 0.00 | 2026-04-10 | 0 | | sleep-neurobiology |
| gap-pubmed-20260410- | Why do NETs specifically accumulate in infarcted core versus penumbra regions af | open | 0.71 | 0.00 | 2026-04-10 | 0 | | neuroinflammation |
| gap-pubmed-20260410- | How does NLRX1 mechanistically promote galectin-3 expression on lysosomes in mic | open | 0.81 | 0.00 | 2026-04-10 | 0 | | neuroinflammation |
| gap-pubmed-20260410- | What upstream mechanisms trigger NLRX1 upregulation specifically in microglia du | open | 0.79 | 0.00 | 2026-04-10 | 0 | | neuroinflammation |
| gap-pubmed-20260410- | What are the optimal clinical trial designs for testing GLP-1RAs in neurodegener | open | 0.82 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | Why do GLP-1RAs show neuroprotective effects in preclinical models but mixed res | open | 0.85 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | How does unilateral nephrectomy specifically enhance indoxyl sulfate's neurotoxi | open | 0.79 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |